[Long-term Outcomes in Eyes Receiving of Bevacizumab Early in the Course of Branch Retinal Vein Occlusion].

Abstract

PURPOSE:

To evaluate the effects of intravitreal bevacizumab (IVB) injections early in the course of branch retinal vein occlusion (BRVO).

PATIENTS AND METHODS:

We conducted a retrospective review of 30 patients (30 eyes) with macular edema (ME) secondary to BRVO. The mean duration from the onset to the first IVB injection was 5 weeks. The mean observation period was 30 months. All patients were followed monthly, with administration of additional IVB injections if there was persistent or recurrent ME within 6 months after the first injection. The main outcome parameter was best-corrected visual acuity (BCVA) at 12 and 24 months. Rescue therapy including laser photocoagulation was done as needed.

RESULT:

Mean BCVA improved significantly from logMAR 0.59 ± 0.24 at baseline to 0.04 ± 0.15 (p < 0.001)at 12 month, 0.06 ± 0.19(p < 0.001)at 24 month.

CONCLUSION:

IVB injections given shortly after onset of branch retinal vein occlusion may result in a significant increase in vision in some patients.

• Authors: Masanori Setta, Shiro Ozaki, Akio Tabuchi
• Journal: Nippon Ganka Gakkai zasshi (Nippon Ganka Gakkai Zasshi) Vol. 120 Issue 5 Pg. 396-402 (May 2016) ISSN: 0029-0203 [Print] Japan
• PMID: 27311272 (Publication Type: English Abstract, Journal Article, Observational Study)

Chemical References

• Bevacizumab

Topics

• Adult
• Aged
• Aged, 80 and over
• Bevacizumab (administration & dosage)
• Humans
• Intravitreal Injections
• Middle Aged
• Retinal Vein Occlusion (drug therapy)
• Retrospective Studies
• Treatment Outcome
• Visual Acuity